https://www.selleckchem.com/pr....oducts/selonsertib-g
In Kaplan-Meier curve, triple-negative (P=0.047) and HR-positive (P=0.006) patients receiving RT had a superior BCSS than that not RT. HER2-positive patients cannot benefit from RT. However, adjusted Kaplan-Meier survival model showed that triple-negative (P=0.019) but not HER2-positive (P=0.575) or HR-positive (P=0.574) patients receiving RT had a superior BCSS than that not RT. Molecular subtype is not associated with the better prognosis of MBC. Patients could benefit from RT. However, triple-negative but not HR-positive
Like
Comment
Share
